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Abstract: Background: Gastro-entero-pancreatic/neuroendocrine (NET) tumors are highly 
vascularized  neoplasms.  However,  our  knowledge  concerning  circulating  levels  of  the 
angiogenic factors in NET patients still remains insufficient. Methods: The aim of this 
study  was  to  measure  plasma  concentrations  of  VEGF,  angiopoietin  1  (Ang-1), 
angiopoietin 2 (Ang-2), soluble Tie-2, endostatin, osteopontin (OPN) and chromogranin A 
(CgA) in 36 NET patients and 16 controls. Results: Only the plasma concentrations of  
Tie-2 and CgA were higher in NET patients as compared to controls. These levels were 
within the reference range in controls; however one control demonstrated slightly elevated 
Tie-2 and 4 elevated CgA. Similarly, in the subgroup of patients with carcinoid syndrome, 
only Tie-2 and CgA concentrations were higher than those in patients with non-functioning 
NETs. In turn, in the subgroup of metastatic patients, only Ang-2 levels were higher than 
in those with localized disease. A positive correlation was found between Ang-2 and Tie-2 
levels in metastatic patients and between Ang-1 and Tie-2 in localized NETs. Conclusions: 
The plasma concentration of Tie-2 is proposed as an additional marker for NET patients 
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and seems to be similarly effective as the currently used CgA level. Moreover, higher 
plasma levels of Ang-2 together with the positive correlation between Ang-2 and Tie-2 
levels in metastatic subjects, implies that cases with a Tie-2 level above the upper limits, 
together with higher level of Ang-2 seem to be highly predictive of metastases.  
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1. Introduction 
Tumor  angiogenesis  is  a  highly  complicated  process  consisting  of  several  steps,  known  as  the 
angiogenesis cascade, regulated by many pro- and antiangiogenic factors, both of endogenous and 
exogenous origin [1,2]. The group of endogenous angiogenic factors comprise, among others, the 
family  of  vascular  endothelial  growth  factors  (VEGFs)  and  their  receptors  (VEGF-A,  VEGF-B, 
VEGF-C, VEGF-D and VGFR-2, VEGFR-3), the family of angiopoietins (Ang) and their receptors 
(Ang-1, Ang-2, Ang3/4 and Tie-1, Tie-2), other growth factor families, as well as endostatin and 
osteopontin  (OPN).  Some  of  these  angiogenic  factors  are  responsible  for  early  activation  of  the 
angiogenic cascade, in which the VEGF signaling pathway acts as the most important early regulator 
of angiogenesis. The angiopoietin signaling pathway controls the later stages of the angiogenic cascade 
related to vessel maturation and quiescence. 
Gastro-entero-pancreatic/neuroendocrine  (NET)  tumors  are  known  to  be  highly  vascularized 
neoplasms. However, our knowledge concerning circulating levels of the angiogenic factors in NET 
patients is rather weak and inconsistent. Since the incidence rate of these tumors has grown rapidly in 
the last two decades, this information seems to be very important not only for diagnostic purposes, but 
also for changes in the therapeutic options. The high vascularization of NETs suggests that the stromal 
cells play a role in tumor development.  
Angiopoietin 1 (Ang-1) is a member of the angiopoietin family of growth factors. It plays a crucial 
role  in  mediating  the  reciprocal  interactions  between  the  endothelium,  surrounding  matrix  and 
mesenchyme. It mediates blood vessel maturation and stability. Ang-1 binds and activates the Tie-2 
receptor tyrosine kinase, which is expressed on the endothelial and lymphatic endothelial cells and 
participates  in  the  regulation  of  angiogenesis  and  lymphangiogenesis  procesess.  Angiopoietin  2  
(Ang-2) competes with this binding, thus blocking receptor phosphorylation and counteracting the 
blood  vessel  maturation  and  stability  mediated  by  Ang-1  [3].
  Its  function,  however,  may  be  
context-dependent. In the absence of angiogenic inducers such as VEGF, Ang-2-mediated loosening of 
cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In 
concert with VEGF, Ang-2 may facilitate endothelial cell migration and proliferation, thus serving as a 
proangiogenic signal. It is known that Ang-2 regulates tumor angiogenesis in cooperation with VEGF, 
as well as with Ang-1, through Tie-2-dependent and independent pathways [4]. 
Endostatin, a 20 kDa fragment of type XVIII collagen inhibits angiogenesis and the growth of many 
tumors [5]. It has been demonstrated that endostatin prevents the activation of the angiogenic process 
and can also induce the regression of some established tumors [6]. In contrast to VEGF, circulating 
levels of endostatin correlate inversely with cancer angiogenesis and relapse-free survival time [7]. Int. J. Mol. Sci. 2012, 13                       
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Although some studies indicate that the antitumor effect of endostatin can be diminished by VEGF [8], 
contradictory  results  showing  either  a  positive  correlation  between  these  factors  [9]  or  no  
correlation [10] have also been published. 
Osteopontin  belongs  to  the  small  integrin-binding  ligand  N-linked  glycoprotein  SIBLING  
family [11]. Its putative functions include roles in bone metabolism, immune response regulation, 
wound  healing  and  tumor  progression  [12].  Growing  evidence  supports  its  role  as  a  potential 
prognostic factor for various human cancers. OPN is expressed on human carcinomas, such as breast 
cancer, where it may have adhesion/migration functions in promoting invasion and metastasis [13]. 
Moreover, elevated OPN levels have been detected in cancer patients, including those with malignant 
mesothelioma [14].  
A few studies have attempted to assess the blood concentrations of angiogenic factors in NET 
patients, but none provide information concerning such a wide panel of factors as that examined in our 
study. The data from a German study collected from 90 NET patients revealed increased Ang-2 serum 
concentration in examined NET subjects as compared to healthy controls. Higher Ang-2 levels were 
observed in metastatic as compared to local stages, which implies that Ang-2 can be applied as a 
prognostic  marker  [15].  Spanish  data  obtained  from  42  NET  patients  showed  enhanced  serum 
concentrations of Ang-1, Ang-2 and soluble Tie-2 as compared to a 27-person control group, and 
revealed  that  Ang-2  and  Tie-2  levels  were  higher  in  patients  with  metastases  compared  to  those 
without [16]. In turn, data from a UK study on 47 NET patients revealed that serum Ang-2 was 
elevated in NET subjects, but not Ang-1. The Ang-2 level was higher in patients with metastases as 
compared to those with local disease [17]. Russian data revealed lower endostatin levels in benign 
NETs than in malignant cases [18]. The aim of the study was to search for new auxiliary diagnostic 
markers for patients with neuroendocrine tumors based on the analysis of six circulating angiogenic 
factors in plasma. 
2. Results and Discussion 
2.1. Patients 
The  characteristics  of  36  patients  with  NETs  including  data  concerning  age,  sex,  metastases, 
hormonal function, localization  of primary tumor  and  somatostatin analog therapy is  presented in 
detail in Table 1. 
Table 1. The characteristics of patients enrolled to the study. 
Patient Characteristics   
Age—median (range)  61 years (31–80) 
Male—number of patients (median of age; range)  17 (57 years; 32–80) 
Female—number of patients (median of age; range)  19 (66 years;31–76) 
Patients with metastatic disease—number of patients (%)  27 (75%) 
Patients without metastases—number of patients (%)  9 (25%) 
Patients with carcinoid syndrome—number of patients (%)  7 (19%) 
Patients with non-functioning NETs—number of patients (%)  29 (81%) Int. J. Mol. Sci. 2012, 13                       
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Table 1. Cont. 
Patient characteristics   
Type of NETs—number of patients (%)   
foregut  11 (31%) 
midgut  12 (33%) 
hindgut  6 (17%) 
unknown or others  7 (19%) 
Localization of the primary tumor—number of patients (%)   
lung  6 (17%) 
thymus  1 (3%) 
pancreas  2 (6%) 
stomach  2 (6%) 
small intestine and appendix  12 (33%) 
rectum  6 (17%) 
unknown or others  7 (19%) 
Concurrent SST analogs—number of patients (%)  14 (39%) 
2.1.1. Angiogenic Factors Levels in Patients with NETs and Healthy Controls 
Patients with NETs had significantly higher plasma levels of Tie-2 (p < 0.001) and CgA (p < 0.001) 
as compared to healthy controls (Figure 1).  
The median of the Tie-2 levels was more than 40% higher than that of the controls while CgA was 
more than 2 times higher. The levels of these factors in the 16 subjects within the control group were 
within reference range, except for 1 subject with slightly elevated Tie-2, and 4 subjects with elevated 
CgA levels. In turn, the levels of Tie-2 and CgA remained within the reference range in 10 and 9 NET 
patients respectively (only one patient had these two factors within normal range). Hence, Tie-2 level 
would  seem  to  be  an  additional  diagnostic  marker  for  NET  patients  and  seem  to  have  a  similar 
effectiveness as the currently-used CgA levels. In addition, in NET patients, a few positive correlations 
were found between Tie-2 and Ang-2 (p < 0.01), Ang-2 and CgA (p < 0.05), as well as endostatin and 
OPN (p < 0.001). Figure 1 shows scatter plots of the angiogenic factor levels with their boundaries of 
reference range and medians in the NET group and healthy controls. 
Moreover, the medians of Ang-1 and Ang-2 levels were also higher in the NET group; in turn, the 
medians of endostatin and OPN were lower than that of the controls, however, the differences did not 
reach the level of statistical significance. 
The main reason why the markedly different median values were not statistically significant is the 
great diversity of the obtained results, especially in the NET group. For example, the range of values in 
the NET group for Ang-1 levels was 836 pg/mL (min) and 74573 pg/mL (max) vs. 2192 pg/mL (min) 
and 45396 pg/mL (max) in controls; and the range for CgA levels in the NET group was 2.4 U/L (min) 
and 809.4 U/L (max), and 4.4 U/L (min) and 109.6 U/L (max) in controls.  Int. J. Mol. Sci. 2012, 13                       
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Figure 1. Plasma angiogenic factors (Ang-1, Ang-2, Tie-2, endostatin, osteopontin (OPN), 
VEGF)  and  CgA  levels  in  NETs  patients  and  controls  (16  volunteers  without  VEGF 
measurements) assessed with ELISA. Solid horizontal lines correspond to the medians of 
plasma levels; in turn, two dashed lines (upper and lower) represent the limits of reference 
values for these factors in EDTA plasma. The reference range for plasma Ang-1 levels is not 
given by kit producer (R&D Systems). Only the plasma levels of Tie-2 (p < 0.001) and CgA 
(p < 0.001) were higher in NET patients as compared to controls (Mann-Whitney U test). 
 Int. J. Mol. Sci. 2012, 13                       
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In controls, a negative correlation was observed between age and CgA (p < 0.05), and between age 
and  Tie-2 levels  (p < 0.01),  but  a  positive  correlation  between  age  and  endostatin concentrations  
(p < 0.05). In controls, the level of CgA positively and strongly correlated with OPN (p < 0.001) and 
weakly with Tie-2 (p < 0.05). Additionally, of all the examined factors in our control group, only the 
levels  of  Ang-2  and  Tie-2  (except  for  one  case)  did  not  go  beyond  the  boundaries  of  reference 
standards  given  in  R&D  Systems  materials.  OPN  levels were  below  the lower limits  in  3 out  of  
16 healthy volunteers, whereas endostatin levels exceeded the upper limits in 13 out of 16 healthy 
controls, which suggest the need to reassess and re-establish new standards for plasma concentrations 
of endostatin (Figure 1).  
2.1.2. Angiogenic Factors Levels in Patients with Carcinoid Syndrome in Comparison to  
Non-Functioning NETs 
NET patients with carcinoid syndrome (7 pts) had significantly higher levels of Tie-2 (more than 
40%, p < 0.05) and CgA (more than 20 times, p < 0.001) as compared to patients with non-functioning 
tumors (29 pts) (Figure 2). Among the patients with carcinoid syndrome none had Tie-2 or CgA levels 
within the reference range. The median levels of factors other than endostatin, OPN and Ang-1 were 
also higher; the median Ang-2 level, for example, was almost 2 times higher, but the differences were 
insignificant. Moreover, a positive correlation was found between endostatin and OPN (p < 0.05 in 
NETs  with  carcinoid  syndrome,  p  <  0.01  in  non-functioning  NETs)  in  both  subgroups,  and  also 
between Ang-2 and Tie-2 in non-functioning tumors (p < 0.05). 
Figure 2. Plasma angiogenic factors (Ang-1, Ang-2, Tie-2, endostatin, OPN, VEGF) and 
CgA levels in patients with carcinoid syndrome (7 pts), non-functioning NETs (29 pts) and 
controls  (16  volunteers  without  VEGF  measurments)  assessed  with  ELISA.  Solid 
horizontal lines  correspond to  the medians  of  plasma  levels; in  turn, two dashed lines 
(upper  and  lower)  represent  the  limits  of  reference  values  for  these  factors  in  EDTA 
plasma. The reference range for plasma Ang-1 levels is not given by kit producer (R&D 
Systems). Only the plasma levels of Tie-2 (p < 0.05) and CgA (p < 0.001) were higher in 
the  subgroup  of  patients  with  carcinoid  syndrome  than  those  in  patients  with  
non-functioning NETs (post hoc Kruskal-Wallis test). 
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Figure 2. Cont. 
 
2.1.3. Angiogenic Factors Levels and Stage of Disease 
In patients with metastatic disease (27 pts), only Ang-2 levels were significantly higher than in NET 
patients with localized disease (9 pts) (p < 0.05): the median value  being more than 45% higher 
(Figure 3). However, there was no correlation between the presence of metastases and Ang-2 levels. In 
metastatic NETs, a positive correlation was found between Ang-2 and Tie-2 levels (p < 0.05), whereas 
in localized NETs a positive correlation was observed between Ang-1 and Tie-2 (p < 0.01). In both 
subgroups, a positive correlation was seen between endostatin and OPN (p < 0.01). The median levels 
of  other  factors,  except  for  OPN,  were  also  higher  in  advanced  disease  but  the  differences  were 
statistically insignificant.  Int. J. Mol. Sci. 2012, 13                       
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Figure 3. Plasma angiogenic factors (Ang-1, Ang-2, Tie-2, endostatin, OPN, VEGF) and 
CgA  levels  in  metastatic  NETs  patients  (27  pts),  NET  patients  with  localized  disease  
(9 pts) and controls (16 volunteers without VEGF measurments) assessed with ELISA. 
Solid horizontal lines correspond to the medians of plasma levels; in turn, two dashed lines 
(upper  and  lower)  represent  the  limits  of  reference  values  for  these  factors  in  EDTA 
plasma. The reference range for plasma Ang-1 levels is not given by kit producer (R&D 
Systems). In the subgroup of metastatic patients, only Ang-2 (p < 0.05) levels were higher 
than in those with localized disease (post hoc Kruskal-Wallis test). 
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Figure 3. Cont. 
 
2.1.4. Angiogenic Factor Level and NET Types 
There  were  no  statistically  significant  differences  between  medians  of  the  examined  levels  of 
factors in patients with foregut, midgut and hindgut NETs, however some correlations were observed 
in each subgroup. In foregut patients, a negative correlation was seen between age and OPN (p < 0.05) 
and between Ang-1 and endostatin (p < 0.05) while a positive correlation was seen between CgA and 
Ang-1 (p < 0.01), endostatin and OPN (p < 0.01) and Ang-2 and Tie-2 (p < 0.05); in midgut patients, 
only  a  positive  correlation  was  observed  between  Ang-1  level  and  VEGF  to  endostatin  ratio  
(p < 0.001); finally, in hindgut patients, a negative correlation was found between Ang-1 and Tie-2  
(p < 0.05) and three positive correlations were found (p < 0.05) between endostatin and Ang-2 to Tie-2 
ratio, OPN and Ang-2 to Tie-2 ratio, and between Tie-2 level and Ang-2 to Ang-1 ratio.  
Ordering the median value of these factors from largest to smallest, a certain regularity can be 
observed. For Tie-2, the highest levels were in the midgut, then the foregut and then the hindgut (53 vs. 
40 vs. 38 ng/mL respectively). For Ang-2, the highest levels were noticed in the midgut, lower in the 
hindgut and the lowest in the foregut (3555 vs. 2823 vs. 2352 pg/mL respectively). The medians for 
Ang-1 in foregut and midgut NETs (14,373 and 14,651 pg/mL respectively) were very close and 
higher than in the hindgut (12,191 pg/mL).The highest median of VEGF levels were observed in 
foregut  NETs,  lower  in  the  midgut  and  the  lowest  in  the  hindgut  (163  vs.  132  vs.  61  pg/mL 
respectively). For endostatin and OPN, the highest to the lowest medians occurred in the opposite 
order to that of VEGF; both factors had the highest median in the hindgut and the lowest in the foregut 
(endostatin: 240 vs. 196 vs. 168 ng/mL; OPN 63 vs. 36 vs. 19 ng/mL respectively).  
2.1.5. Changes in Angiogenic Factors Levels in Selected NET Patients, Who Had Two Blood  
Samples Taken 
Double blood sampling in 4 out of 36 patients allows the changes in concentrations of examined 
angiogenic  factors  to  be  analyzed  with  passing  time  and,  in  3  patients,  after  the  introduction  of 
somatostatin analog therapy. The characteristics of these 4 patients, including data concerning sex, age, 
metastases,  hormonal  function,  the  type  of  NET,  time  of  the  introduction  of  somatostatin  analog 
therapy, their dosages and time of treatment, together with the levels of examined angiogenic factors 
and the changes in their levels expressed in percent, is presented in detail in Table 2. Int. J. Mol. Sci. 2012, 13                       
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Table 2. Changes in angiogenic factors levels in four NET patients, who had two blood 
samples taken. 
Patient 
Time of Two Blood  
Samplings & Changes 
CgA 
(U/L) 
Tie-2 
ng/mL 
Ang-2 
(pg/mL) 
Ang-1 
(pg/mL) 
End 
ng/mL 
OPN 
ng/mL 
VEGF 
(pg/mL) 
♀ 
69-year-old 
metastatic non-
functioning 
midgut NET 
(small intestine) 
1/before the first injection of  
20 mg octreotide LAR 
(Novartis) 
34.8  64  16921  13571  208  123  ND 
2/one month later, 
before the second injection 
ND  43  3024  8228  160  123  ND 
changes    ↓30%  ↓80%  ↓40%  ↓20%  0%   
♂ 
57-year-old 
metastatic midgut 
NET with 
carcinoid 
syndrome 
1/before the first injection of  
90 mg lanreotide autogel 
(Ipsen) 
492  37  2062  13671  296  65  ND 
2/after 7 months of therapy  
(90 mg every 4 weeks) with 
well-controlled symptoms 
678.5  42  4086  5231  232  52.5  ND 
changes  ↑40%  ↑10%  ↑100%  ↓60%  ↓20%  ↓20%   
♂ 
47-year-old 
metastatic 
non-functioning 
NET of the left 
kidney 
1/good clinical status,  
2 months before the first dose 
of 20 mg 
octreotide LAR (Novartis) 
75.7  38  3708  27102  92  14  370.6 
2/poor clinical status, just 
before death, after 1 year and  
1 month of octreotide therapy 
(20 mg every 4 weeks) and 
after many resections of 
metastatic foci 
60.8  25  3376  28362  100  13  314.3 
changes  ↓19%  ↓34%  ↓9%  ↑5%  ↑8%  ↓7%  ↓13% 
♂ 
57-year-old 
metastatic non-
functioning rectal 
NET and gastric 
GIST 
 
1/just before GIST removal on 
octreotide therapy 
11.1  48  1406  2217  144  6  ND 
2/after almost 2 years passed, 
without new GIST foci and 
with partial regression of NET 
metastatic foci, continuously 
treated with octreotide LAR for 
3 years and 6 months 
(Novartis) 20 mg i.m. every  
4 weeks 
13.2  43.5  2823  7701  240  63  ND 
changes 
↑ 
19% 
↓ 
10% 
↑ 
100% 
↑ 
350% 
↑ 
160% 
↑ 
1000% 
ND 
CgA: chromogranin A; Tie-2: soluble form Tie-2; Ang-1, -2: angiopoetin 1, 2; End: endostatin, OPN: osteopontin, VEGF: 
vascular endothelial growth factor; ↓: decrease; ↑: increase; ND: not determined. 
In one of these patients (69-year-old woman, Table 2), a dramatic decrease in the levels of all 
examined factors except OPN was observed 1 month after the first injection of octreotide LAR, at 
almost  unchanged  clinical  status.  In  the  next  one  (57-year-old  man,  Table  2)  with  significant 
improvement in clinical status observed after 7 months of lanreotide autogel therapy (despite of an Int. J. Mol. Sci. 2012, 13                       
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increase of CgA levels), the levels of Ang-1, OPN and endostatin decreased, whereas of Ang-2 and 
Tie-2 increased. In another one (47-year-old man, Table 2), the second sampling was performed just 
before  his  death,  at  very  poor  clinical  status  after  1  year  and  1  month  of  octreotide  therapy  and 
revealed a drop in Ang-2, Tie-2, OPN and VEGF levels together with a rise in Ang-1 and endostatin. 
In the last patient (57-year-old man, Table 2), the blood was taken for the second time after almost  
2 years since the removal of gastric GIST, at the time when partial regression of NET foci together 
with disappearance of symptoms were noticed, and revealed a huge rise in the levels of all the factors 
except Tie-2. 
2.1.6. Discussion 
This  is  the  first  study  assessing  the  levels  of  so  many  angiogenic  factors  (Ang-1,  -2,  Tie-2, 
endostatin, OPN and VEGF) in patients with NETs, in order to ascertain the profile of these factors 
and their mutual correlation with the hope of finding among them new additional diagnostic markers 
for these unpredictable tumors. In some ways our data is unique because the levels of these factors 
have been evaluated in plasma instead of serum to avoid the influence of platelets.  
The levels of these factors differ significantly between serum and plasma. The reference ranges for 
these factors are much narrower, and the upper limits of the normal values much smaller, in plasma 
than in serum (the plasma values for Ang-2, Tie-2 are half the serum values and the VEGF upper limit 
is almost 6 times smaller in plasma than serum) apart from those of OPN, whose serum values achieve 
about  50%  of  the  plasma  values  (artificially  decreased  by  thrombin  proteolytic  cleavage).  This 
regularity is caused by platelets, which have the ability of selective uptake of all angiogenic factors in 
cancer-bearing individuals [19]. As a result, these factors are released from platelets into the serum 
during platelet activation when the clot is forming. Thus, the plasma levels of these factors reflect 
circulating protein content, while serum levels reflect the sum of plasma content and the amount of 
factors released from platelets during their activation.  
However,  the  released  amount  of  angiogenic  factors  from  platelets  depends  on  a  number  of 
variables. Firstly, the number of platelets is important, and hence, some authors who are aware of this 
phenomenon,  present  serum  levels  of  these  factors  with  a  correction  for  platelet  count  based  on  
Adams et al. [20]. Secondly, the time of platelet activation can have an influence. For example, during 
the clot formation in a clot-activator tube, the amount of the released VEGF increases with time and 
reaches a plateau after 60 min. Hence, in some papers, the blood samples were allowed to clot for  
2 h [21]. Finally, the type of platelet activator, such as ADP, thrombin or clot-activator tube, and the 
type of angiogenic factors, for example VEGF or bFGF, can have an influence [19]. Moreover, the 
released amount of angiogenic factors from platelets can be also changed by antiplatelet drugs such as 
aspirin [22] and perhaps by other factors.  
The  influence  of  even  a  small  number  of  platelets  in  plasma  prepared  according  to  standard 
procedures (recommended by the National Committee for Clinical Laboratory Standards) is highlighted 
by  the  instructions  given  in  R&D  Systems  materials,  where  the  company  advises  an  additional 
centrifugation  step  for  complete  platelet  removal  (platelet-free  plasma)  to  avoid  variable  and 
irreproducible  results.  Moreover,  the  company  does  not  give  the  reference  range  for  Ang-1 Int. J. Mol. Sci. 2012, 13                       
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concentrations in plasma prepared according to the typical procedure, hence the lack of two horizontal 
lines representing the boundaries of the reference range on our figures.  
Therefore, as the platelets seem to be the richest source of the aforementioned substances and can 
selectively take up or release them in an unpredictable way, the plasma levels of the examined factors 
may be superior and, undoubtedly, more stable than their serum concentrations. 
In our study, of all the factors examined, only the plasma levels of soluble Tie-2 and CgA were 
elevated in patients with NETs as compared to the healthy controls. Therefore, we would suggest Tie-2 
peripheral blood plasma concentration as new additional diagnostic marker for NET patients. In our 
opinion,  it  seems  to  be  similarly  effective  as  the  currently  used  CgA  level.  The  number  of  false 
positive and false negative results detected in our study favors even Tie-2 over CgA levels; only one 
person from healthy controls had an elevated (above upper limit of normal) level of Tie-2, as opposed 
to 4 with an increased CgA level. Additionally, while Tie-2 levels were within reference range for  
10 NET patients, CgA levels remained within the reference range for 9 NET patients.  
In  other  cited  studies  concerning  NET  patients,  the  levels  of  these  factors  were  evaluated 
exclusively in serum, which makes the comparison rather difficult. Moreover, it has been shown that 
the levels of VEGF [21] or endostatin [22] do not correlate in serum and plasma.  
Despite this inconsistency a survey of the literature reveals that our results are concordant with data 
from Spain (the only study in which Tie-2 levels were measured in NET patients) in which elevated 
levels of Tie-2 were observed in NET patients when compared to the controls [16]. The authors also 
noticed elevated levels of Ang-1 and Ang-2, which were not shown in our study. In the Spanish report, 
Tie-2 levels in the healthy subjects were found to overlap those of NET patients much more frequently, 
although there is no precise description of the overlapping data in the cited paper [16]. Although the 
levels of Tie-2 in both this and the Spanish studies were assessed by the same experimental kit (R&D 
Systems), the results did not reveal the expected differences between serum and plasma levels (higher 
levels in serum than in plasma); in the Spanish study, the serum Tie-2 level in NET patients was 25.9 ±  
9.5 (X ±  SD) ng/mL vs. controls 17.1 ±  4.1 ng/mL whereas in our study, the plasma Tie-2 level in NETs 
was 43 (25–95) ng/mL (median and range) vs. control 30 (23–35) ng/mL.  
In contrast to our results, the Spanish report also revealed higher Tie-2 and Ang-2 levels in patients 
with metastases as compared to those without. In our patients’ samples, only the plasma Ang-2 levels 
were  higher in  metastatic  as  compared  to local  NET subjects.  This  finding  is  consistent  with the 
English [17] and German [15] studies, where Ang-2 levels were assessed in serum unlike to our study.  
However,  in  all  these  studies,  the  results  from  both  NET  subgroups  (metastatic  and  localized) 
overlapped. In this event, the positive correlation between Ang-2 and Tie-2 levels observed by us only 
for metastatic patients may be helpful in diagnostic evaluation. Cases with a combination of a Tie-2 
level above the upper limits, together with a rather high level of Ang-2 seem to be highly indicative of 
metastases. In our study, 20 out of 27 patients with metastases had elevated Tie-2 levels. In turn, the 
concentrations of Tie-2 and CgA were within reference range only in 7 and 6 out of 27 metastatic 
patients respectively suggest an important role of Tie-2 in NET progression. Moreover, two positive 
correlations seen in our patients, one between Ang-2 and Tie-2 in metastatic patients, and the second 
between Ang-1 and Tie-2 in localized NETs, seem to be obvious, when taking into consideration the 
physiological role of these angiomodulators in angiogenesis.  Int. J. Mol. Sci. 2012, 13                       
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Similarly, no expected differences regarding Ang-2 levels were observed between ours (plasma) 
and the other studies (serum), especially in control subjects, although the same kit from R&D Systems 
was used by all the authors. In our study, the median of Ang-2 levels in controls was 2380 pg/mL; in 
the study from England—2495 pg/mL; from Germany—2650 pg/mL and from Spain—1.7 ng/mL 
(arithmetic mean).  
In our opinion, the differences between biological materials (plasma and serum) cannot be solely 
responsible for the presented discrepancies between this study and the others. Instead, it may well be 
due to the unusual heterogeneity of NET tumors. The recommendation from the consensus report of 
the  National  Cancer  Institute  that  ”carcinoid  tumors  and  pancreatic  NETs  should  be  examined 
separately” is still not taken into consideration in ours and other studies [23]. However, with this in 
mind, our study concerns mainly non-pancreatic NETs with only 2 pancreatic cases (6%), whereas 
pancreatic NETs were strongly represented in other reports: in the study from England, 17 out of  
47 (36%); from Germany, 25 out of 42 (60%) and from Spain, 23 out of 42 patients (55%). 
Moreover,  some  discrepancies  between  the  Spanish  and  English  data,  for  example,  concerning 
Ang-1 levels, which are elevated in NET patients from Spain but not from England, can be caused by 
the difference in the number of platelets; although both studies measured the levels of this factor in 
serum, none gave any information about the platelet count. 
Other data from our study did not reach the threshold of statistical significance, however the paucity 
of  published  data  concerning  the levels  of  angiogenic  factors  in  NET  patients  demand  that  some 
interesting, in our opinion, observations be highlighted. Namely, the levels of angiogenic factors are 
not stable in NET patients and can be changed drastically even within a very short period of time (one 
month),  as was observed in  one  of our  patients.  Most likely, these major changes, and the small 
decrease in VEGF concentration observed in our other patient, may be caused by somatostatin analog 
treatment, which is in accordance with on in vitro study showing the inhibition of VEGF secretion 
from neuroendocrine tumor cells by octreotide [24,25]. In addition, the endostatin and OPN levels in 
our  studies  were  found  to  be  rather  low  in  NET  patients  in  comparison  to  healthy  controls, 
contradicting  the  findings  of  the  other  studies,  which  show  elevated  OPN  levels  in  patients  with 
mesothelioma [14] or endostatin in renal cell carcinoma patients [9] and others. Finally, our study is 
the first in the literature in which OPN levels were evaluated in patients with NETs. 
3. Materials and Methods 
3.1. Patients 
Thirty-six NET patients were enrolled between May 2008 and February 2011 to the study. All the 
patients had neuroendocrine tumors as confirmed histologically by morphological assessment as well 
as by immunohistochemical analysis for chromogranin A (CgA), synaptophysin and, where it was 
possible, by Ki67 evaluation according to the 2000 WHO classification for gastrointestinal tract and 
from  2004  for  the  bronchopulmonary  tract.  All  36  cases  were  classified  as  well-differentiated 
neuroendocrine tumors or cancers. All these patients were diagnosed and treated at the outpatient 
endocrinology clinic and at the Department of Clinical Endocrinology, Medical University of Lodz, 
Poland. The study was approved by the by the Ethics Committee of the Medical University of Lodz. Int. J. Mol. Sci. 2012, 13                       
 
 
1457 
The written informed consent was obtained from all participants before blood sampling after a full 
explanation of the purpose of the study and the nature of all procedures. 
Plasma samples from all patients were collected during routine examinations for CgA assessment; 
this was performed just before the drug injection in most patients treated with somatostatin analogs. In 
4 out of 36 patients, plasma samples were collected twice at different time points due to important 
reasons which are supposed to influence upon the examined parameters, such as the introduction of 
somatostatin analog therapy. These patients are described in detail in the results section. The other data 
concerning these patients, such as age, sex, localization of the primary tumor, presence of metastases, 
hormonal  function  and  somatostatin  analog  therapy  were  obtained  from  systemic  review  of  the 
appropriate medical documentation. The control groups comprised 16 healthy volunteers (age- and 
gender-matched) enrolled in the same period. All of them are employees at the Chair of Endocrinology, 
Medical University of Lodz and had no previous history of cancer. 
3.2. ELISAs 
Venous blood samples were collected into vacutainer tubes supplemented with EDTA from all the 
patients  and  control  volunteers.  The  samples  were  centrifuged  at  1000xg  for  15  minutes  within  
30 minutes of collection and stored at −20 
oC. ELISA kits from R&D Systems (Quantikine Human 
VEGF, Quantikine  Human  Angiopoietin-1, Quantikine Human  Angiopoietin-2, Quantikine Human 
TIE-2,  Quantikine  Human  Endostatin,  Quantikine  Human  Osteopontin)  were  used  to  measure  the 
concentrations of the following angiogenic factors in the plasma samples: VEGF (assessed only at  
20 NET patients due to financial limits), Ang-1, Ang-2, soluble Tie-2, endostatin and OPN. The assay 
Quantikine  Human  VEGF  is  designated  to  measure  the  levels  of  VEGF165  in  various  biological 
materials.  It  is  a  proangiogenic  form  of  VEGF  A  in  contrast  to  its  anti-angiogenic  splice  
variant—VEGF165b.  All  these  assays  employ  the  quantitative  sandwich  enzyme  immunoassay 
technique by using a microplate precoated with a monoclonal antibody specific to an appropriate factor. 
Chromogranin A was measured by a Dako ELISA kit (Chromogranin A ELISA kit), which utilizes 
rabbit antibodies specific to a 23 kDa C-terminal fragment of human chromogranin A. It was decided 
to evaluate the plasma levels of these factors to avoid the well-known effect of platelets on the levels 
of these factors in serum [19]. In addition, it is recommended that osteopontin should be assayed in 
plasma in order to avoid cleavage by thrombin during the clotting process. 
3.3. Statistical Analysis 
Statistical analysis was performed using Statistica 9 Software [26]. Since the obtained data was not 
normally distributed (the Shapiro-Wilk test), the non-parametric Mann-Whitney U test (for two groups) 
or  Kruskal-Wallis  test  (for  several  groups)  were  used  to  compare  differences  between  examined 
groups. The Spearman correlation coefficient was used to analyze correlations between parameters. 
Differences were considered significant if p < 0.05. Moreover, a trial version of Graph Pad Software 
[27] was used to create all figures in order to present each separate result, which is not possible using 
Statistica 9 Software. Int. J. Mol. Sci. 2012, 13                       
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4. Conclusions 
Summing up, enhanced  peripheral blood  plasma Tie-2 concentration seems to be an additional 
diagnostic marker for NET patients offering a similar effectiveness as the currently used CgA levels. 
Moreover, higher plasma levels of Ang-2 together with the positive correlation between Ang-2 and 
Tie-2  levels  in  metastatic  subjects,  implies  that  cases  with  a  Tie-2  level  above  the  upper  limits, 
together with higher level of Ang-2 seem to be highly predictive of metastases. 
Acknowledgments  
This  work  has  been  supported  with  the  contribution  of  European  Cooperation  in  the  field  of 
Scientific and Technical Research—COST ACTION, Grant No. CM0602 and by Polish Ministry of 
Science and Higher Education, Grant No. 505-04-001. 
The  funders  had  no  role  in  study  design,  data  collection  and  analysis,  decision  to  publish,  or 
preparation of the manuscript. 
Conflict of Interest 
The authors declare no conflict of interest. 
References 
1.  Stepien,  H.M.;  Kołomecki,  K.;  Pasieka,  Z.;  Komorowski,  J.;  Stepień,  T.;  Kuzdak,  K. 
Angiogenesis of endocrine gland tumours—New molecular targets in diagnostics and therapy. 
Eur. J. Endocrinol. 2002, 146, 143–151. 
2.  Turner, H.E.; Harris, A.L.; Melmed. S; Wass, J.A. Angiogenesis in endocrine tumors. Endocr. 
Rev. 2003, 24, 600–632. 
3.  Fiedler, U.; Krissl, T.; Koidl, S.; Weiss, C.; Koblizek, T.; Deutsch, U.; Martiny-Baron, G.; Marmé , 
D.; Augustin, H.G. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-
2  receptor  involving  the  first  Ig-like  loop  and  the  epidermal  growth  factor-like  repeats.  
J. Biol. Chem. 2003, 278, 1721–1727. 
4.  Hu, B.; Cheng, S.Y. Angiopoietin-2: development of inhibitors for cancer therapy. Curr. Oncol. 
Rep. 2009, 11, 111–116. 
5.  O’Reilly,  M.S.;  Boehm,  T.;  Shing,  Y.;  Fukai,  N.;  Vasios,  G.;  Lane,  W.S.;  Flynn,  E.;  
Birkhead, J.R.; Olsen, B.R.; Folkman, J. Endostatin: An endogenous inhibitor of angiogenesis and 
tumor growth. Cell 1997, 88, 277–285. 
6.  Bergers,  G.;  Javaherian,  K.;  Lo,  K.M.;  Folkman,  J.;  Hanahan,  D.  Effects  of  angiogenesis 
inhibitors on multistage carcinogenesis in mice. Science 1999, 284, 808–812. 
7.  Kuroi, K.; Tanaka, C.; Toi, M. Circulating levels of endostatin in cancer patients. Oncol. Rep. 
2001, 8, 405–409. 
8.  Schuch, G.; Kisker, O.; Atala, A.; Soker, S. Pancreatic tumor growth is regulated by the balance 
between positive and negative modulators of angiogenesis. Angiogenesis 2002, 5, 181–190.  Int. J. Mol. Sci. 2012, 13                       
 
 
1459 
9.  Feldman,  A.L.;  Alexander,  H.R.,  Jr.;  Yang,  J.C.;  Linehan,  W.M.;  Eyler,  R.A.;  Miller,  M.S.; 
Steinberg, S.M.; Libutti, S.K. Prospective analysis of circulating endostatin levels in patients with 
renal cell carcinoma. Cancer 2002, 95, 1637–1643. 
10.  Schips,  L.;  Dalpiaz,  O.;  Lipsky,  K.;  Langner,  C.;  Rehak,  P.;  Puerstner,  P.;  Pummer,  K.;  
Zigeuner, R. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal 
cell carcinoma patients compared to a control group. Eur. Urol. 2007, 51, 168–173. 
11.  Fisher, L.W.; Fedarko, N.S. Six genes expressed in bones and teeth encode the current members 
of the SIBLING family of proteins. Connect. Tissue Res. 2003, 44, 33–40.  
12.  Rittling, S.R.; Chambers, A.F. Role of osteopontin in tumour progression. Br. J. Cancer 2004, 90, 
1877–1881.  
13.  Sharp, J.A.; Sung, V.; Slavin, J.; Thompson, E.W.; Henderson, M.A. Tumor cells are the source 
of osteopontin and bone sialoprotein expression in human breast cancer. Lab. Invest. 1999, 79, 
869–877.  
14.  Creaney, J.; Yeoman, D.; Musk, A.W.; de Klerk, N.; Skates, S.J.; Robinson, B.W. Plasma versus 
serum levels of osteopontin and mesothelin in patients with malignant mesothelioma—Which is 
best? Lung Cancer 2011, 74, 55–60. 
15.  Detjen,  K.M.;  Rieke,  S.;  Deters,  A.;  Schulz,  P.;  Rexin,  A.;  Vollmer,  S.;  Hauff,  P.;  
Wiedenmann,  B.;  Pavel,  M.;  Scholz,  A.  Angiopoietin-2  promotes  disease  progression  of 
neuroendocrine tumors. Clin. Cancer Res. 2010, 16, 420–429.  
16.  Figueroa-Vega,  N.;  Dí az,  A.;  Adrados,  M.;  Alvarez-Escolá ,  C.;  Paniagua,  A.;  Aragoné s,  J.; 
Martí n-Pé rez, E.; Leskela, S.; Moreno-Otero, R.; Gonzá lez-Amaro, R.; et al. The association of 
the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in 
neuroendocrine tumors. Endocr. Relat. Cancer 2010, 17, 897–908.  
17.  Srirajaskanthan, R.; Dancey, G.; Hackshaw, A.; Luong, T.; Caplin, M.E.; Meyer, T. Circulating 
angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease 
burden and prognosis. Endocr. Relat. Cancer 2009, 16, 967–976. 
18.  Polikarpova,  S.B.;  Lyubimova,  N.V.;  Smirnova,  E.A.;  Britvin,  T.A.;  Ogereliev,  A.S.;  
Davidov, M.I. Serum angiogenic factors in patients with neuroendocrine tumors of abdominal 
organs. Bull. Exp. Biol. Med. 2009, 148, 634–637.  
19.  Klement, G.L.; Yip, T.T.; Cassiola, F.; Kikuchi, L.; Cervi, D.; Podust, V.; Italiano, J.E.; Wheatley, 
E.; Abou-Slaybi, A.; Bender, E.; et al. Platelets actively sequester angiogenesis regulators. Blood 
2009, 113, 2835–2842.  
20.  Adams, J.; Carder, P.J.; Downey, S.; Forbes, M.A.; MacLennan, K.; Allgar, V.; Kaufman, S.; 
Hallam, S.; Bicknell, R.; Walker, J.J.; et al. Vascular endothelial growth factor (VEGF) in breast 
cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of 
tamoxifen. Cancer Res. 2000, 60, 2898–2905.  
21.  Colleoni, M.; Rocca, A.; Sandri, M.T.; Zorzino, L.; Masci, G.; Masci, G.; Nolè , F.; Peruzzotti, G.; 
Robertson, C.; Orlando, L.; et al. Low-dose oral methotrexate and cyclophosphamide in metastatic 
breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. 
Ann. Oncol. 2002, 13, 73–80. Int. J. Mol. Sci. 2012, 13                       
 
 
1460 
22.  Holmes, C.E.; Huang, J.C.; Pace, T.R.; Howard, A.B.; Muss, H.B. Tamoxifen and aromatase 
inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women 
with breast cancer. Clin. Cancer Res. 2008, 14, 3070–3076. 
23.  Kulke, M.H.; Siu, L.L.; Tepper, J.E.; Fisher, G.; Jaffe, D.; Haller, D.G.; Ellis, L.M.; Benedetti, J.K.; 
Bergsland, E.K.; Hobday, T.J.; et al. Future directions in the treatment of neuroendocrine tumors: 
consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning 
meeting. J. Clin. Oncol. 2011, 29, 934–943.  
24.  Villaume,  K.;  Blanc,  M.;  Gouysse,  G.;  Walter,  T.;  Couderc,  C.;  Nejjari,  M.;  Vercherat,  C.; 
Cordier-Bussat, M.; Roche, C.; Scoazec, J.Y. VEGF secretion by neuroendocrine tumor cells is 
inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 
2010, 91, 268–278. 
25.  Melen-Mucha, G.; Lawnicka, H.; Kierszniewska-Stepien, D.; Komorowski, J.; Stepien, H. The 
place  of  somatostatin  analogs  in  the  diagnosis  and  treatment  of  the  neuoroendocrine  glands 
tumors. Recent Pat. Anticancer Drug Discov. 2006, 1, 237–254. 
26.  Statistica 9, version 9; StatSoft Inc.: Tulsa, OK, USA, 2009. 
27.  Graph Pad Prism, trial version; GraphPad Software Inc.: La Jolla, CA, USA, 2010. 
© 2012 by  the authors; licensee  MDPI,  Basel, Switzerland. This  article is  an  open  access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 